Cancer drugs could reach $80 billion by 2011: IMS.
IMS expects growth to be fueled by the introduction of 25 to 30 new chemical entities between 2008 and 2012, as expensive new biotechnology drugs and the increasing use of combination therapies contribute to the exploding cost of treatment. Data from clinical studies of many of the newest cancer drugs will be presented and discussed later this month in Chicago. Several factors could serve to moderate growth over the next five years, IMS said. They include financial constraints of payers, slowing growth of some current blockbuster therapies and patent expirations of four cancer drugs with annual sales exceeding $1 billion, including Eli Lilly & Co.'s (Indianapolis IN) Gemzar and Taxotere from France's Sanofi-Aventis SA.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||TOP STORIES|
|Article Type:||Brief article|
|Date:||May 19, 2008|
|Previous Article:||Sunrise Senior Living Inc's (McClean VA) first-quarter revenue under management rose 11% as the company opened new facilities and increased occupancy...|
|Next Article:||Merck says appeals court overturns Vioxx verdict.|